
KLOW80 mg Blend
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
KLOW, explained simply
A blend of TB-500, BPC-157, KPV, and GHK-Cu, assembled around research hypotheses involving tissue repair and inflammation.
Research area
Tissue repair, skin matrix and inflammatory signalling
How it works
Research links TB-500 and BPC-157 to repair models, KPV to inflammatory signalling, and GHK-Cu to collagen processes.
Why it matters
The profile separates the blend's composition from findings available for each ingredient.
What has been observed
Most cited observations are preclinical or concern individual components; they do not establish a clinical effect of the combination.
Effects and points to consider
Interactions and safety of the mixture cannot be inferred by simply adding up proposed component effects.
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Total vial mass | 80 mg |
|---|---|
| Component masses | GHK-Cu: 50 mg; BPC-157: 10 mg; TB-500: 10 mg; KPV: 10 mg |
| Final volume | 3 mL |
| Concentration | 26.67 mg/mL |
| Frequency | once daily |
| Cycle | 12 in table |
Standard / Gradual Approach (3 mL = ~26.7 mg/mL Total)
| Week | Daily Dose (per component) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg | 7.5 units (0.075 mL) |
| Weeks 3–4 | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
| Weeks 5–8 | TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg | 22.5 units (0.225 mL) |
| Weeks 9–12 (Maintenance) | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
Supplies needed


Sterile alcohol swabs
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.